What is it?
ACP-196 is a second generation Bruton’s tyrosine kinase (BTK) inhibitor that can be taken orally. It was developed as an alternative to ibrutinib and was designed to be more selective in targeting BTK. Like ibrutinib it inhibits BTK, a protein important in the development, activation, proliferation, and survival of B-cells. ACP-196 is currently being investigated as a treatment for various B-cell lymphomas, as well as chronic lymphocytic leukemia (CLL).
How does ACP-196 work?
ACP-196 works by inhibiting the activity of BTK, a protein important in the development of B-cells. By preventing the activation of the B-cell antigen receptor signaling pathway, it slows down the growth of cancerous B-cells caused by the overactive BTK.
Does ACP-196 have any side effects?
The side effects for ACP-196 are acceptable and manageable with very few side effects being considered severe.
What is the difference between ACP-196 and ibrutinib?
ACP-196 and ibrutinib are similar in that they both inhibit BTK using the same binding site. They also are both effective in treating chronic lymphocytic leukemia cells. The difference is that ACP-196 inhibits fewer off target enzymes. By being more specific for BTK, the drug may have fewer side effects than ibrutinib, while maintaining similar anti-cancer activity.
How can I access ACP-196?
There are currently numerous clinical trials opened at Weill Cornell Medicine that use ACP-196 for various indications of CLL and B-cell lymphomas. A full list can be found on our Joint Clinical Trials website.
The Weill Cornell Lymphoma Program has recently opened a new research study for men and women with previously-treated chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib. The study is sponsored by the Acerta Pharma BV and the principal investigator is John Allan, MD. For more information about the study, please call Amelyn Rodriguez at 212-746-1362 or email her at email@example.com.
- Men and women age 18 and older.
- Diagnosis of CLL.
- At least one prior therapy for CLL.
- Intolerant to ibrutinib.
- Detailed eligibility reviewed when you contact the study team.
Btk inhibition is an established therapeutic intervention for the treatment of CLL. In February 2014, ibrutinib (IMBRUVICA®) monotherapy, the first Btk inhibitor developed for clinical use, was approved in the United States for the treatment of patients with CLL who have had ≥ 1 prior therapy or 17p deletion based on high response rates with few drug-related toxicities. However, ibrutinib is not without its adverse reactions. This study will evaluate the safety and efficacy of the second-generation Btk inhibitor, ACP-196, in subjects who have previously discontinued ibrutinib therapy due to adverse reactions. Preliminary data to date suggests that ACP-196 is very well tolerated and has robust activity as a single agent in the treatment of subjects with relapsed/refractory CLL. Additionally, PK/PD results show the 100-mg BID regimen produces optimal target coverage over 24 hours, which may provide greater clinical benefit than the QD regimen of ibrutinib. This study will explore whether ACP-196, as an alternative Btk inhibitor, with a potentially distinct safety profile, may fill an unmet need in therapeutic options for patients who are intolerant to ibrutinib.
Subjects will receive ACP-196 orally twice daily continuously throughout the study as long as they are responding to therapy and not experiencing unacceptable side effects. Subjects who are continuing to tolerate and derive clinical benefit from treatment at the end of the trial may continue to receive their study treatment after discussion with the medical monitor. After discontinuing treatment, subjects will remain in long-term follow-up until loss to follow-up, consent withdrawal, or study closure.
In this video from Patient Power, CLL Program Director, Dr. Richard Furman discusses recent results on chronic lymphocytic leukemia (CLL) presented in abstracts during the 2015 meeting of the American Society of Hematology (ASH) and the place of newly targeted therapies including ABT-199 and ACP-196 in treating patients with CLL.
Dr. Furman has previously written about CLL abstracts from the 2015 ASH meeting here and here. More information about available CLL trials at Weill Cornell Medicine can be found on the Joint Clinical Trials website.